ArticleCancer immunology, immunotherapy : CII2025

Sustained remission with PD-1 and BTK inhibitors maintenance after chimeric antigen receptor T-cell therapy in CNS lymphoma.

Lingzi Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.